Gilead Sciences Inc. has identified new GTPase KRAS G12D mutant inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS G12D mutant-targeting moiety potentially useful for the treatment of cancer.